Royalty Report: Drugs, Disease, Therapeutic – Collection: 279348

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Disease
  • Therapeutic
  • Hair loss
  • Dermatology
  • cardiac

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 279348

License Grant
Licensor grants
—  during the Research Term, a non-exclusive, worldwide, license, without the right to sublicense, under the Licensor Technology solely to perform Licensees obligations under the Research Plan; and
—  an exclusive, worldwide license, including the right to sublicense, under the Licensor Technology and Licensors interest in the Joint Patent Rights, to develop, make, have made, use, sell, have sold, offer for sale and import Selected Compounds and Products solely in the Licensee Field.
License Property
Licensor possesses scientific and proprietary technology and data and resources relating to the Hedgehog Pathway.  Hedgehog Pathway shall mean the biological signaling cascade which stimulates the transcription of various genes that mediate Hedgehog-dependent phenotypic cellular changes, as evidenced by the upregulation of transcription of Gli.

Product shall mean any final dosage form of a pharmaceutical product containing a Selected Compound for use in the Licensee Field.

Field of Use
Licensee possesses scientific and technical resources relating to the development and commercialization of pharmaceutical products for the treatment of skin diseases and/or disorders or for the promotion of hair growth in humans.

Licensor Field shall mean the local administration of Excluded Compounds for
—  the treatment or prevention of cardiovascular diseases and disorders in humans, including but not limited to the use of an Excluded Compound coated on a cardiovascular stent and ex vivo use of Excluded Compounds for the preparation of cells to be used in cell therapy applications; and/or any other indication in humans (excluding any indication within the Licensee Field) to which Licensor obtains rights from Third Party after the Effective Date; and/or
—  the Veterinary Field.  Veterinary Field shall mean Topical Application of a Licensed Compound for the treatment or prevention of any skin disease or disorder in animals, excluding humans.

Licensee Field shall mean the Topical Application of a Selected Compound or Product for the promotion of hair growth in humans (Hair Growth lndications); and/or any other indication in which Topical Application is used in humans – each, a Skin-Related Indication.

IPSCIO Record ID: 230770

License Grant
For the exclusive licenses, Licensor grants
– during the Research Term, the exclusive worldwide right and license to use the Licensor Technology to the extent necessary to conduct the Research Program;
– during the Evaluation Tail, the exclusive worldwide right and license to use the Licensor Technology to the extent necessary to determine whether any of the then identified Hit Compounds or Activator Compounds can become Lead Compounds and to further screen and conduct selectivity testing of any Lead Compounds identified in the Research Term for the purpose of determining whether Licensee will select any such Lead Compounds as Development Candidates;
– the exclusive right and license to use the Licensor Technology to develop and have developed Agreement Compounds and Products and to make, have made, use, import, export, market, offer for sale, sell and have sold Products in the Territory for use in the Licensee Field; and
– if Licensee exercises the Licensee Option with respect to any Option Compound, the exclusive right and license to use the Licensor Technology to develop and have developed such Option Compound and any Option Product containing such Option Compound and to make, have made, use, import, export, market, offer for sale, sell and have sold such Option Products in the Territory for use in the Licensee Field.
License Property
Licensor possesses scientific and proprietary technology and data and resources relating to the Hedgehog Pathway.

The Product shall mean any final dosage form of a pharmaceutical product containing a Development Compound, independent of indication, route of administration, or dosage strength or form.

Agreement Protein shall mean the Hedgehog protein,as described in U.S. Patent #6,384,192, and any proteins and polypeptides, included in the Licensor Technology, which have preferential binding affinity foe the Hedgehog proteins natural receptor.

Compound shall mean a small molecule or macromolecule compound (including. without limitation, the Agreement Protein), together with all complexes, mixtures and other combinations, pro~drugs, metabolites, enantiomers, salt forms, racemates and isomers thereof.

Field of Use
Licensee desires to obtain a license to this proprietary technology to further develop and commercialize pharmaceutical products for the treatment of, among other diseases, neurodegenerative diseases and neuropathies.

Licensors Field shall mean the topical administration of Activator Compounds or Agreement Protein for the promotion of  hair growth and the Local Administration of Activator Compounds for the treatment of cardiovascular diseases, including but not limited to the use of an Activator Compound coated on a cardiovascular stent.

Licensees Field shall mean the treatment or prevention of diseases and/or disorders in humans.

The Research Field means the discovery, characterization, design, development and commercialization of Compounds for the treatment or prevention of neurodegenerative diseases or conditions and/or neuropathies wherein such Compounds exert such therapeutic, prophylactic or other beneficial effects are achieved, in whole or in material part, through Pathway Activator Activity.

IPSCIO Record ID: 383570

License Grant
The University grants to Licensee of Bermuda an exclusive, worldwide right and license, with the right to sublicense, under University Patent Rights to make, have made, use, sell, offer for sale and import Product in the Field of Use during the Term.
License Property
The University owns and controls certain innovative technology for regrowth of hair.

The patents are
— Prostaglandin D2 Synthase and its Products as Cause of Hair Loss and Target for Therapy;
— Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia.

Field of Use
The Field of Use means hair growth and hair removal in humans.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.